DJIA 16,408.54 -16.31 -0.10%
NASDAQ 4,095.52 0.00 0.00%
S&P 500 1,864.85 2.54 0.14%
market minute promo

Nektar Therapeutics

NASDAQ: NKTR



company name or ticker

Nektar Presents Pipeline Data - Analyst Blog

MannKind Rival, Also Developing Inhaled Insulin Device, Files $75M IPO

Nektar Rises on FDA Notification (revised) - Analyst Blog

NKTR Makes Notable Cross Below Critical Moving Average

Nektar Rises on FDA Notification - Analyst Blog

Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape

Wider-than-Expected Loss at Nektar, Guidance Disappoints - Analyst Blog

Nektar Therapeutics' CEO Discusses Q4 2013 Results - Earnings Call Transcript

3 Under-the-Radar Biotech Stocks You Need to Watch in 2014

Nektar Therapeutics, Omeros, and Spectrum Pharmaceuticals all face off with regulators in key decision dates for their developmental drugs later this year

Can Nektar Therapeutics Beat Pfizer Inc.?

In addition to Remoxy, Pfizer has an in-house formulation of abuse-resistant oxycodone in late stage trials. Could an all new opioid from Nektar Therapeutics upend both programs?
See More Articles...